RE:RE:RE:RE:RE:10% drop for whatYeah, but it would be so useful to have this data to be able to corelate any efficacy with real sortilin expression. That's the big freakin hole in all of this story. I still don't understand how you can develop a targeted drug without precisely assessing the level of target expression and location. If this strategy is valid, efficacy is supposed to be dependant on the "quality" of sortilin expression. Other factors can play a role to hamper efficacy, like taxanes resistance, but without proper sortilin expression, failure is assured.
SPCEO1 wrote: "Patient selection has also been refined to focus on those who are less heavily pretreated, with no more than one taxane failure and a maximum of eight prior cancer treatment regimens."
Not what you were hoping for but I imagine they think sortilin is overexpressed enough in ovarian cancer that there is limited utility in a screening for it before treatment? jfm1330 wrote: Nothing on protocol for patient selection, have I missed something?